Ocugen price target raised to $22 from $15 at Lucid Capital

By TheFly | March 11, 2026, 6:10 AM

Lucid Capital analyst Elemer Piros raised the firm’s price target on Ocugen (OCGN) to $22 from $15 and keeps a Buy rating on the shares. The company announced positive preliminary Phase 2 data for OCU410 in geographic atrophy, the analyst tells investors in a research note.

Claim 70% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on OCGN:

Disclaimer & Disclosure Report an Issue

Mentioned In This Article

OCGN

+4.86%

Ocugen Inc

Latest News

May-05	Ocugen: Q1 Earnings Snapshot OCGN -19.46% Associated Press
May-05	Ocugen Provides Business Update with First Quarter 2026 Financial Results OCGN -19.46% GlobeNewswire
May-05	Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes OCGN -19.46% GlobeNewswire
May-04	Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes OCGN GlobeNewswire
Apr-29	Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results OCGN GlobeNewswire
Apr-23	Ocugen to Present at April 2026 Investor and Industry Conferences OCGN GlobeNewswire
Apr-10	Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells OCGN -5.88% PR Newswire
Apr-01	Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease OCGN GlobeNewswire
Mar-27	Can Ocugen succeed where other gene therapy makers have struggled? OCGN Pharma Voice
Mar-25	Ocugens GA gene therapy garners mixed sentiments on 12-month Phase II readout OCGN Clinical Trials Arena
Mar-24	Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration OCGN -8.57% GlobeNewswire
Mar-23	Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410-Modifier Gene Therapy for Geographic Atrophy OCGN GlobeNewswire
Mar-11	Ocugen price target raised to $22 from $15 at Lucid Capital OCGN +29.94% TipRanks
Mar-10	Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? OCGN +6.63% Zacks
Mar-04	Ocugen, Inc. Q4 2025 Earnings Call Summary OCGN +5.38% Moby

Ocugen price target raised to $22 from $15 at Lucid Capital

Claim 70% Off TipRanks Premium

Mentioned In This Article

Latest News

Upgrade your Finviz experience